All investor lists > Biotech

Biotech Investors & VC Firms

Browse OpenVC's database of investors funding startups in biotech, life sciences, and healthcare innovation.

Last update: August 21, 2025

List author: Lucas Roquilly

Shortlist investors, submit pitch decks, and get replies

Download the OpenVC investor dataset
|
|
Premium filters
102 investors 

Raising Capital for Your Biotech Startup? Here’s What You Need to Know.

Raising money for a biotech startup isn’t exactly like fundraising for SaaS or AI. If you’ve made it past a seed round already, you’re likely familiar with the necessity for massive capital upfront, long development timelines, and high regulatory risk. Investors are well aware of this—and they’re looking for startups with strong science, clear commercialization pathways, and a team that can execute over the long haul.

Unlike traditional tech startups that can pivot quickly, biotech is a commitment. If you’re aiming to find a lead investor for your startup, you need to prove that your startup is positioned to make it through preclinical, clinical, and regulatory hurdles.

Next, we’ll cover everything you need to know about securing biotech funding.

What Biotech Investors Look for in a Startup

Biotech investors know that most startups won’t generate revenue for years—sometimes a decade or more. That’s why they focus on the following criteria:

Strong Scientific Validation – Investors need clear, defensible science backed by preclinical or early clinical data. If you’re still in the idea phase, VCs won’t bite.

Intellectual Property (IP) & Competitive Advantage – Your patents, licensing agreements, or proprietary tech must create a real barrier to entry.

Clear Regulatory Pathway – The FDA approval process is long and complex. Investors will ask: What’s your timeline? What phase are you in? Are there precedents for similar drugs or devices getting approved?

Capital Efficiency & Funding Milestones – Investors need to see a clear use of funds and how each financing round gets you closer to commercialization.

🚩 Biggest red flags for biotech investors

  • Unclear path to regulatory approval
  • No clear commercialization plan
  • Weak team composition (Lack of a diverse team or credible advisors)

How to Raise Capital in Biotech

Your startup should always have a defined fundraising strategy, especially in the early stages. Before planning too much out, here are some basic biotech funding principles you should be aware of.

Who invests in biotech?

🔹 Biotech-Focused VCs: (ARCH Venture Partners, Flagship Pioneering, Third Rock Ventures)
🔹 Corporate & Pharma VCs: (Pfizer Ventures, Novartis Venture Fund, Roche Venture Fund)
🔹 Generalist VC Firms Investing in Biotech: (Andreessen Horowitz Bio + Health, Sequoia, Khosla Ventures)

What’s expected at each stage?

💰 Pre-seed: A promising scientific breakthrough, strong founding team, and early research grants.
💰 Seed: Preclinical validation, early IP protection, and a clear regulatory plan.
💰 Series A+: Clinical trial progress, strong industry partnerships, and an FDA roadmap.

How long does biotech fundraising take?

  • Early-stage (preclinical): 6-12 months
  • Clinical-stage (Phase 1+): 12+ months
  • Go-to-market (post-approval): Depends on partnerships & commercialization strategy

How to Pitch Biotech Investors and Win Funding

What biotech investors expect in a pitch

📊 Compelling scientific rationaleWhy does your technology work? What’s the mechanism of action?
🚀 Regulatory strategyWhat’s your FDA/EMA approval pathway, and how long will it take?
💡 Commercial potentialWho pays for your innovation (insurers, hospitals, pharma companies)?

Common biotech pitch mistakes that cost you funding

  • Overpromising timelines. Investors know drug development takes time—be realistic about milestones.
  • Lack of a clear reimbursement strategy. If insurers won’t cover it, commercialization will be tough.
  • Weak clinical or preclinical data. If your results aren’t statistically significant, investors won’t bite.

Key slides in a biotech pitch deck

Building a startup pitch deck can be daunting, especially in the biotech sphere. Let’s be sure you cover the key aspects investors will be watching out for:

🚨 Problem Slide – Define the unmet medical need or scientific challenge your startup is solving, setting the stage for why investors should care.

💡 Solution Slide – Showcase your breakthrough innovation (drug, therapy, platform) and explain why it’s scientifically and commercially superior.

🗺️ Roadmap Slide – Biotech investors think in milestones—this slide should detail where you are in the clinical/regulatory process and when key inflection points (IND, Phase 1, FDA approval) will occur.

💰 Financials Slide – Between this and the Ask Slide, investors want to see how much capital you need, how it will be spent, and when you’ll need the next round.

👥 Team Slide – Highlight scientific credibility, regulatory experience, and industry expertise to prove you can execute. (Be sure to include advisors).

VC vs. Grants, Nonprofits, and Government Capital

Biotech startups have two primary funding paths: venture capital and non-dilutive funding (grants, nonprofits, and government programs). Each has trade-offs, and the right choice depends on your startup’s risk tolerance, stage, and speed to market.

Let’s explain.

Venture capital: fast money, high expectations

VC funding provides millions in capital but comes at a cost.

  • Takes equity – Parting with equity is never easy, but it's critical for biotechs to grow.
  • Fast-tracks commercialization – This can get you to market much faster.
  • High pressure, high expectations – Investors expect significant gains quickly,
  • Industry connections & strategic support – Top biotech VCs bring access to key partnerships, expertise, and future funding rounds.

Grants, nonprofits, and government capital: non-dilutive but slow

Non-dilutive funding allows startups to raise capital without giving up ownership. But retaining equity isn’t free of drawbacks.

  • No equity dilution – You keep full control of your company.
  • Highly competitive & slow approval – NIH, SBIR/STTR, BARDA, and disease foundations offer funding but require long application cycles.
  • Best for early-stage validation – Grants can fund preclinical research, but they don’t typically cover commercialization.
  • Patient advocacy & nonprofit funding – Some foundations and nonprofits provide funding for startups tackling rare diseases and public health issues.

If you need to fund early-stage R\&D, go after grants first, because free money beats dilution. But if you’re scaling into clinical trials or commercialization, VCs move faster, write bigger checks, and open doors. However, expect high pressure and a clear path to ROI.

Types of Biotech Innovations Hot Right Now

Here are just a few areas in biotechnology that are rapidly capturing headlines and catching the attention of investors. If you are among these on the list, know that VCs are keeping a close eye on your market’s landscape.

📌 AI-driven drug discovery
📌 Gene editing & CRISPR advancements
📌 Personalized medicine & precision therapeutics
📌 Synthetic biology & biomanufacturing
📌 Longevity & anti-aging research
📌 RNA-based therapies (beyond mRNA vaccines)
📌 Next-generation diagnostics & biomarker discovery

Find the Best Biotech Investors and VC Firms on OpenVC

Lastly, here’s how you can use OpenVC for FREE and gain access to biotech investors actively funding startups like yours 🚀

  • Browse 5,000+ investors – Filter by industry, stage, geography, check size, and more.
  • Submit your pitch deck directly – Find investors who care (faster than any other outreach strategy) and directly send them your pitch deck.
  • Get replies – Chat with potential investors through OpenVC (did we mention it’s free?)
  • Close your round – Secure the funding your biotech needs to scale.

🔥 Join OpenVC now to start connecting with top biotech investors instantly.

Frequently Asked Questions

OpenVC is a free fundraising platform where startup founders can search verified investors,  submit their pitch decks, and manage their entire raise. Users can search 20,000+ verified investors, shortlist the right ones, and submit your pitch deck directly. Our CRM, deck analytics, and warm intro tools help you run a smarter, more organized raise.

Founders raise with OpenVC because it is designed to cut through the noise and get founders in front of the right investors, fast. With built-in tools for CRM, analytics, and warm intros, it helps you stay organized and improve your chances of getting a reply.

OpenVC is for early-stage startup founders who want to raise capital efficiently. Find investors from dozens of industries including SaaS, AI, fintech, biotech, and more. Whether you’re pre-seed, seed, or Series A, OpenVC helps you find and pitch aligned investors without paying intro fees, aimlessly cold-emailing, or scraping databases.

Yes, OpenVC is completely free to use. You can search investors, submit your pitch deck, track engagement, and manage your raise—all without paying a cent. Premium features are available, but the core platform is free and always will be.

You create a free OpenVC account, build your investor shortlist, and submit your pitch deck directly through the platform. Investors receive a unique link to view your deck, and you get analytics on who opens it and how long they spend on it. No cold emails, no guesswork. For more info, check out our complete guide to fundraising on OpenVC.

Absolutely, OpenVC is designed for early-stage fundraising. You’ll find thousands of angel investors, pre-seed VCs, accelerators, incubators, and family offices who are actively backing startups across sectors and geographies. Use OpenVC’s filters to narrow your search and find the right investors for your startup.

Some examples of startups that successfully secured funding through OpenVC include Mobly (2.5M seed), Paxum ($1.2M seed), and Laennec AI ($400k pre-seed). OpenVC startups have gone on to raise more than $1 billion from top venture capital firms like YC, Sequoia, Google Ventures, and M12.

OpenVC was created by Stephane Nasser and Lucas Roquilly—two founders building tools to make startup fundraising more transparent and accessible. We launched OpenVC to help founders find investors, get replies, and raise smarter. The platform is bootstrapped, community-driven, and built with a lot of heart.

More investor lists

OpenVC startups have raised
$1+ billion from: